טוען...
Potentiation of PD-L1 blockade with a potency-matched dual cytokine–antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains
We have recently described a novel therapeutic antibody product (IL2–F8–TNF(mut)), featuring the simultaneous fusion of murine IL2 and of a TNF mutant with scFv(F8), an antibody specific to the alternatively-spliced extra domain A of fibronectin (EDA). Here, we report on the in vivo characterization...
שמור ב:
| הוצא לאור ב: | Cancer Immunol Immunother |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer Berlin Heidelberg
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6129175/ https://ncbi.nlm.nih.gov/pubmed/29971465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-018-2194-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|